Pfizer Lifts Full-Year Outlook as Bourla Prepares for London Fireside Chat
Published on 11/11/2026 at 04:41 | Editorial boerse-global.de
Pfizer has raised its sights for the full year after a third-quarter performance that came in well ahead of what the market had been expecting. The pharmaceutical giant now projects 2026 revenue of $62.0bn to $64.0bn, with adjusted diluted earnings per share of $2.95 to $3.05 — both ranges lifted alongside the quarterly release roughly a week ago.
The numbers behind that upgrade were solid. Revenue for the third quarter of 2026 reached $16.58bn, comfortably above the $15.85bn consensus tracked by FactSet. Adjusted diluted EPS came in at $0.87. Reuters attributed the momentum to robust demand for Eliquis and for Padcev, the cancer drug Pfizer picked up through acquisition.
A Split Analyst Verdict
Opinion on the stock is not unanimous. DZ Bank reportedly cut its rating from Buy to Hold on Friday while setting a $33 price target. Freedom Broker moved the other way on the same day, lifting its target from $33 to $34 and reaffirming its Buy call. The two houses thus find themselves on opposite sides of the fence: one has withdrawn its previous bullish stance, the other has kept the faith.
Should investors sell immediately? Or is it worth buying Pfizer?
Shares gained 0.9% in the prior session to close at €26.29.
Bourla Takes the Stage in London
Investor attention now turns to November 17, 2026, when chief executive Albert Bourla will appear at the Jefferies London Healthcare Conference. Pfizer has announced a public webcast of the discussion, scheduled to begin at 9:00 GMT, with both audio and video available to shareholders and the wider public. Registration details were expected to be made available starting today.
Finance Chief Change and Pipeline News
On the corporate side, Pfizer confirmed on November 3 the appointment of Cecile Guegan as chief financial officer and executive vice president, effective November 1. She succeeds Dave Denton.
The company has also been busy on the research front. Edison Scientific announced an agreement with Pfizer on October 29 to deploy its AI platform, along with Kosmos, across Pfizer's biopharmaceutical R&D pipeline. About two weeks earlier, Pfizer reported a phase 3 win for ELREXFIO in the MagnetisMM-32 study, which met its primary endpoint on progression-free survival versus investigator's choice of standard therapies in patients with relapsed or refractory multiple myeloma. And on October 26, the FDA broadened the approval of TALZENNA in combination with XTANDI to cover metastatic hormone-sensitive prostate cancer harbouring mutations in HRR genes.
Ad
Pfizer Stock: New Analysis - 11 November
Fresh Pfizer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
